-
2010
8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...
-
Meet us
The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...
Danegaptide/ZP1609 Publications
Piatnitski Chekler, E.L., Butera, J.A., Di, L., Swillo, R.E., Morgan, G.A., Rossman, E.I., Huselton, C., Larsen, B.D., Hennan, J.K.
Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents
Bioorg.Med.Chem.Lett., 2009, 4551-4554
Laurent, G., Leong-Poi, H., Mangat, I., Moe, G.W., Hu, X., So, P.P-S., Tarulli, E., Ramadeen, A., Rossman, E.I., Hennan, J.K., Dorian, P.:
Effects of Chronic Gap Junction Conduction–Enhancing Antiarrhythmic Peptide GAP-134 Administration on Experimental Atrial Fibrillation in Dogs.
Circ Arrhythmia Electrophysiol. 2009, 2, 171-178
Hennan, J.K., Swillo, R.E., Morgan, G.A., Rossman, E.I., Kantrowitz, J., Butera, J., Petersen, J.S., Gardell, S.J. and Vlasuk, G.P.:
GAP-134 ([2S,4R]-1-[2-Aminoacetyl]-4-Benzamidopyrrolidine-2-Carboxylic Acid) Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs.
J. Cardiovasc. Pharmacol. Therapeut. 2009, 14, 207-214
Rossman, E.I., Liu, K., Morgan, G.A., Swillo, R.E., Krueger, J.A., Gardell, S.J., Butera, J., Gruver, M., Kantrowitz, J., Feldman, H.S., Petersen, J.S., Haugan, K. and Hennan, J.K.:
The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.
J. Pharmacol. Exp. Ther. 2009, 329, 1127-1133
Butera, J.A., Larsen, B.D., Hennan, J.K., Kerns, E., Di. L., Alimardanov, A., Swillo, R.E., Morgan, G.A., Liu, K., Wang, Q., Rossman, E.I., Unwalla, R. McDonald, L., Huselton, C., Petersen, J.S.:
Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an Orally Active Small Molecule Gap-Junction Modifier for the Treatment of Atrial Fibrillation.
J Med Chen, 2009, 52, 908-911
Laurent, G., Leong-Poi,H., Moe, G., Hu, X., So, P.-S.S., Ramadeen, A., Doumanovskaia, L., and Konig, A.:
Effects of Oral Gap Junction Conduction-Enhancing Antiarrhythmic Peptide GAP-134 on Experimental Atrial Fibrillation in Dogs
Abstract from The American Heart Association Meeting and Scientific Sessions 2007, Orlando, Florida, USA, Nov. 3-7, 2007.
Rossman, E.I., Liu, K., Morgan, G.A., Swillo, R.E., Butera, J., Gruver, M., Kantrowitz, J., Haugan, K., Petersen, J.S. and Hennan, J.K.:
Effects of the Gap Junction Modifier, GAP-134, on Conduction and Atrial Fibrillation/Flutter Inducibility in Dogs
Abstract from The American Heart Association Meeting and Scientific Sessions 2007, Orlando, Florida, USA, Nov. 3-7, 2007.
Butera, J.A., Larsen, B.D., Kerns, K., Di, L., Hennan, J.K., Swillo, R., Morgan, G., Huselton, C., Unwalla, R. and Petersen, J.S.:
The Discovery of Potent Gap-junction Modifiers as Novel Antiarrhythmic Agents - From Stable Hexa-peptides to Orally Available Small Molecules.
Abstract for American Chemistry Society Fall Meeting 2007, August 19-23, 2007, Boston, MA, USA
Hennan, J.K., Liu, K., Morgan, G., Swillo, R., Butera, J., Kantrowitz, J., Haugan, K., Larsen, B.D., and Petersen, J.S.:
Pharmacological characterization of GAP-134, an orally bioavailable small molecule gap junction modifier, in mouse, rat and canine arrhythmia models
Abstract p 95, International Gap Junction Conference, Elsinore, Denmark, 4-7 August 2007
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.
Home Legal Disclaimer Updated: 27.7.2010